A Pilot Double-blind, Placebo-controlled Crossover Study to Explore the Possible Benefit of AUT00063, an Oral Modulator of Voltage-gated Potassium Channels, in Adult Post-lingual Unilateral Cochlear Implant Recipients: The QuicK+fire-study

Trial Profile

A Pilot Double-blind, Placebo-controlled Crossover Study to Explore the Possible Benefit of AUT00063, an Oral Modulator of Voltage-gated Potassium Channels, in Adult Post-lingual Unilateral Cochlear Implant Recipients: The QuicK+fire-study

Completed
Phase of Trial: Phase II

Latest Information Update: 29 May 2017

At a glance

  • Drugs AUT 00063 (Primary)
  • Indications Hearing loss
  • Focus Therapeutic Use
  • Acronyms The QuicK+fire-study
  • Sponsors Autifony Therapeutics
  • Most Recent Events

    • 23 May 2017 Status changed from active, no longer recruiting to completed.
    • 13 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 17 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top